Diagnostic tests

While the news about advances in Alzheimer’s research has been steady over the past several years, including new treatment options that can potentially slow down cognitive decline, along with better ways of diagnosing Alzheimer’s at an earlier stage, there have not been gob smacking advances that have left researchers excited…

The data has been concerning even before the release of the most recent report. With more than 6 million Americans currently diagnosed with dementia (that’s nearly 10% of people 65 and older), more than 100,000 deaths a year attributable to dementia, and more than $600 billion in annual dementia caregiving…

Not very long ago, we highlighted the advent of a new blood test to detect colon cancer. While we made clear its accuracy in detecting early-stage colon cancer is not equal to that of a traditional colonoscopy, for those who have not undergone a colonoscopy or other screening tests, it…

Not very long ago we brought you the news that a new blood test had been developed to test for colorectal (CRC) cancer. This past week, the FDA approved the test, called Shield, produced by the drug manufacturer Guardant. Endorsed by both the American Cancer Society and the US Preventive…

If it feels like there’s an onslaught of information these days about how to diagnose and treat Alzheimer’s dementia, your feelings are valid. New developments and research are coming fast and furious, as academic researchers and for-profit companies race to find effective ways to diagnose Alzheimer’s as early as possible…

In the evolving landscape of the diagnosis and treatment of Alzheimer’s, updates and insights are regularly advancing. We’ve previously reported on the introduction and demise of the first breakthrough “treatment”- Aduhelm- and then on the introduction of Leqembi, the IV-administered antibody intended to slow down the pace of cognitive decline…